199 related articles for article (PubMed ID: 35796785)
1. A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan.
Ishizawa K; Yokoyama M; Kato H; Yamamoto K; Makita M; Ando K; Ueda Y; Tachikawa Y; Suehiro Y; Kurosawa M; Kameoka Y; Nagai H; Uoshima N; Ishikawa T; Hidaka M; Ito Y; Utsunomiya A; Fukushima K; Ogura M
Cancer Chemother Pharmacol; 2022 Jul; 90(1):83-95. PubMed ID: 35796785
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
[TBL] [Abstract][Full Text] [Related]
3. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ogura M; Uchida T; Taniwaki M; Ando K; Watanabe T; Kasai M; Matsumoto Y; Shimizu D; Ogawa Y; Ohmachi K; Yokoyama H; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2054-8. PubMed ID: 20594195
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ohmachi K; Ando K; Ogura M; Uchida T; Itoh K; Kubota N; Ishizawa K; Yamamoto J; Watanabe T; Uike N; Choi I; Terui Y; Usuki K; Nagai H; Uoshima N; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2059-64. PubMed ID: 20626754
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
[TBL] [Abstract][Full Text] [Related]
10. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
Gao Y; Liu Y; Wang Y; Zhang Q; Wu D; Ye X; Wu J; Xu W; Zhou J; Yang Y; Cen H; Zhang F; Xiang Y; Tang X; Ding K; Lin J; Ma L; Wang S; Yu H; Zhao Y; Song B; Lv F; Huang H
Cancer; 2023 Feb; 129(4):551-559. PubMed ID: 36541221
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
13. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Maddocks K; Christian B; Jaglowski S; Flynn J; Jones JA; Porcu P; Wei L; Jenkins C; Lozanski G; Byrd JC; Blum KA
Blood; 2015 Jan; 125(2):242-8. PubMed ID: 25355819
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K
Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613
[TBL] [Abstract][Full Text] [Related]
15. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Matsumoto Y; Kobayashi T; Shimura Y; Kawata E; Nagoshi H; Ohshiro M; Sugitani M; Shimura K; Iwai T; Fuchida SI; Yoshida M; Kiyota M; Mizutani S; Chinen Y; Takimoto-Shimomura T; Nakao M; Kaneko H; Uchiyama H; Uoshima N; Nishigaki H; Kobayashi Y; Horiike S; Shimazaki C; Taniwaki M; Kuroda J;
Int J Hematol; 2019 Jul; 110(1):77-85. PubMed ID: 31127456
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of bendamustine-rituximab combination therapy for newly diagnosed indolent B-cell non-Hodgkin's lymphoma and elderly mantle cell lymphoma: a multi-center prospective phase II clinical trial in China].
Wang H; He Q; Liu D; Deng XZ; Ma J; Xie LN; Sun ZL; Liu C; Zhao RR; Lu K; Chu XX; Gao N; Wei HC; Sun YH; Zhong YP; Xing LJ; Zhang HY; Zhang H; Xu WW; Li ZJ
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):550-554. PubMed ID: 37749033
[No Abstract] [Full Text] [Related]
17. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR
Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083
[TBL] [Abstract][Full Text] [Related]
18. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
Itoh K; Igarashi T; Irisawa H; Aotsuka N; Masuda S; Utsu Y; Tsujimura H; Tsukasaki K; Wakita H
Leuk Lymphoma; 2018 Jul; 59(7):1606-1613. PubMed ID: 29081255
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
Budde LE; Wu D; Martin DB; Philip M; Shustov AR; Smith SD; Gooley TA; Chen TL; Libby EN; Chen EY; Kojouri K; Langerak A; Roden JE; Press OW; Gopal AK
Br J Haematol; 2018 Nov; 183(4):601-607. PubMed ID: 30596402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
